Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.
Type | Public | |
Founded | 2000 | |
HQ | Cambridge, MA, US | Map |
Website | merrimack.com | |
Employee Ratings | More |
USD | |
---|---|
Net income (Q3, 2020) | (1.0m) |
EBIT (Q3, 2020) | (1.0m) |
Market capitalization (20-Jan-2021) | 101.6m |
Closing stock price (20-Jan-2021) | 7.6 |
Cash (30-Sept-2020) | 15.8m |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 11.3m | 12.1m | 11.3m | 14.7m | 18.5m | 6.9m | 13.0m | 27.8m | 28.0m | 14.8m | 36.6m | 16.4m | 21.3m | 33.7m | 28.1m | ||||||||||||
Cost of goods sold | 711.0k | 1.9m | 1.0m | ||||||||||||||||||||||||
Gross profit | 20.6m | 31.8m | 27.1m | ||||||||||||||||||||||||
Gross profit Margin, % | 97% | 94% | 96% |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 30.6m | 32.0m | 27.9m | 28.4m | 30.9m | 105.5m | 66.9m | 77.8m | 100.3m | 28.8m | 33.7m | 56.4m | 48.2m | 21.5m | 36.5m | 17.2m | 135.5m | 107.2m | 34.3m | 22.5m | 49.8m | 36.5m | 36.9m | 20.9m | 18.0m | 15.7m | 15.8m |
Accounts Receivable | 6.0m | 6.9m | 6.1m | 9.8m | 14.5m | 8.8m | 12.2m | 6.6m | 2.6m | 4.2m | 1.8m | 2.1m | 15.6m | 19.3m | 22.2m | 43.0k | 43.0k | 190.0k | |||||||||
Prepaid Expenses | 6.5m | 6.6m | 11.3m | 10.2m | 9.2m | 8.9m | 2.5m | 4.4m | 5.8m | 3.2m | 5.4m | 6.4m | 4.5m | 4.6m | 4.1m | 2.3m | 5.9m | 8.0m | 844.0k | 1.7m | 1.8m | 4.6m | 2.1m | 1.5m | 1.9m | 3.6m | 2.9m |
Inventories | 8.1m | 12.3m | 14.8m |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (23.3m) | (43.3m) | (66.5m) | (28.2m) | (58.2m) | (98.3m) | (27.8m) | (46.0m) | (74.1m) | (34.4m) | (57.3m) | (99.7m) | (38.7m) | (89.6m) | (119.9m) | (30.2m) | 480.7m | 483.8m | (17.8m) | (35.6m) | (31.6m) | (10.5m) | (19.9m) | (20.6m) | 249.0k | (914.0k) | (1.9m) |
Depreciation and Amortization | 1.4m | 2.2m | 3.0m | 700.0k | 1.3m | 1.9m | 886.0k | 2.2m | 2.8m | 1.1m | 2.1m | 4.3m | 1.5m | 3.0m | 5.2m | 1.2m | 2.1m | 2.8m | 1.2m | 2.3m | 3.2m | 1.2m | 2.2m | 2.2m | |||
Inventories | (4.4m) | (8.4m) | (10.7m) | ||||||||||||||||||||||||
Accounts Payable | (2.1m) | (1.9m) | (3.9m) | 6.9m | 11.4m | 19.7m | (4.5m) | (6.0m) | (2.1m) | 4.6m | 7.5m | 335.0k | (1.2m) | (7.1m) | (2.4m) | 8.1m | 2.5m | (3.1m) | (2.4m) | (2.0m) | 1.1m | (4.5m) | (9.9m) | (10.1m) | 215.0k | (435.0k) | (496.0k) |
USD | Q1, 2012 |
---|---|
Financial Leverage | -0.2 x |
Merrimack Pharmaceuticals has 1.09k Twitter Followers. The number of followers has decreased 0.8% month over month and decreased 0.8% quarter over quarter
When was Merrimack Pharmaceuticals founded?
Merrimack Pharmaceuticals was founded in 2000.
Who are Merrimack Pharmaceuticals key executives?
Merrimack Pharmaceuticals's key executives are Richard Peters.
How many employees does Merrimack Pharmaceuticals have?
Merrimack Pharmaceuticals has 27 employees.
Who are Merrimack Pharmaceuticals competitors?
Competitors of Merrimack Pharmaceuticals include Enochian BioSciences, Mirati Therapeutics and Del Mar Pharmaceuticals.
Where is Merrimack Pharmaceuticals headquarters?
Merrimack Pharmaceuticals headquarters is located at 1 Kendall Square, Cambridge.
Where are Merrimack Pharmaceuticals offices?
Merrimack Pharmaceuticals has an office in Cambridge.
How many offices does Merrimack Pharmaceuticals have?
Merrimack Pharmaceuticals has 1 office.
Receive alerts for 300+ data fields across thousands of companies